retatrutide trial dose Breaking: New data just released. TRIUMPH-1 study results on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg retatrutide trial dose dosing clinical

Hassan N, Rashad M, Elleithy E, Sabry Z, Ali G, Elmosalamy S

A behavioural neuroscientist by training, Sophie has spent 30 years working at the intersection of medical research, pharmacology, technology and patient communication across the pharmaceutical industry, health technology and charity sectors

Semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are synthetic versions of GLP-1

Ignoring persistent symptoms often delays effective treatment

Pubmed 17(1):175 Landrigan PJ, Goldman LR (2011) Childrens vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy

Douros A, Filion KB, Yin H, et al